Tumor radiosensitization by monomethyl auristatin E: Mechanism of action and targeted delivery

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1376-1387

  Buckel, Lisa ^a   Savariar, Elamprakash N ^b   Crisp, Jessica L ^b   Jones, Karra A ^c   Hicks, Angel M ^a   Scanderbeg, Daniel J ^a   Nguyen, Quyen T ^d   Sicklick, Jason K ^e   Lowy, Andrew M ^e   Tsien, Roger Y ^b,f   Advani, Sunil J ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b San Diego   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; PACLITAXEL; VEDOTIN; ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; OLIGOPEPTIDE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VIVO STUDY; IONIZING RADIATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; HCT 116 CELL LINE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DRUG DELIVERY SYSTEMS; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942880991     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1931     Document Type: Article

References (48)

1. Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 2013; 10: 323-33.
2. Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol 2010; 7: 437-47.
3. Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 2011; 8: 649-59.
4. Pretz JL, Wo JY, Mamon HJ, Kachnic LA, Hong TS. Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. Surg Oncol Clin N Am 2013; 22: 511-24.
5. Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov 2013; 12: 526-42.
6. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med 2013; 5: 173sr2.
7. Raleigh DR, Haas-Kogan DA. Molecular targets and mechanisms of radio-sensitization using DNA damage response pathways. Future Oncol 2013; 9: 219-23.
8. Terasima T, Tolmach LJ. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 1963; 3: 11-33.
9. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 122: 613-7.
10. Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990; 39: 1941-49.
11. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778-84.
12. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64: 15-29.
13. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004; 101: 17867-72.
14. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009; 1: 371-81.
15. Olson EA, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, et al. Invivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009; 1: 382-93.
16. Whitney M, Crisp JL, Olson ES, Aguilera TA, Gross LA, Ellies LG, et al. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J Biol Chem 2010; 285: 22532-41.
17. Crisp JL, Savariar EN, Glasgow HL, Ellies LG, Whitney MA, Tsien RY. Synergistic targeting of integrin avb3 and matrix metalloprotienase-2 improves optical imaging oftumors and chemotherapeutic efficiency. Mol Cancer Therapeutics 2014; 13: 1514-25.
18. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphav-beta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001; 263: 209-23.
19. Savariar EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P, et al. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res 2013; 73: 855-64.
20. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006; 12: 2591-6.
21. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. Anantibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014; 74: 1214-26.
22. Liu FF, Okunieff P, Bernhard EJ, Stone HB, Yoo S, Coleman CN, et al. Lessons learned from radiation oncology trials. Clin Cancer Res 2013; 19: 6089-100.
23. Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, et al. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst 2013; 105: 686-93.
24. Miller SM, Wang AZ. Nanomedicine in chemoradiation. Ther Deliv 2013; 4: 239-50.
25. Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, et al. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as anovel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013; 86: 463-8.
26. Joh DY, Sun L, Stangl M, Al Zaki A, Murty S, Santoiemma PP, Davis JJ, et al. Selective targeting of brain tumors with gold nanoparticle-induced radio-sensitization. PLoS One 2013; 8: e62425.
27. Wang Y, Mo L, Wei W, Shi X. Efficacy and safety of dendrimer nanoparticles with coexpression of tumor necrosis factor-a and herpes simplex virus thymidine kinase in gene radiotherapy of the human uveal melanoma OCM-1 cell line. Int J Nanomedicine 2013; 8: 3805-16.
28. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12: 329-32.
29. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-91.
30. Mezhir JJ, Advani SJ, Smith KD, Darga TE, Poon AP, Schmidt H, et al. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res 2005; 65: 9479-84.
31. Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, et al. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther 2011; 18: 1098-102.
32. Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, et al. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin. Cancer Res 2012; 18: 2579-90.
33. Hallahan DE, Qu S, Geng L, Cmelak A, Chakravarthy A, Martin W, et al. Radiation-mediated control of drug delivery. Am J Clin Oncol 2001; 24: 473-80.
34. Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E, et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 2003; 3: 63-74.
35. Hariri G, Yan H, Wang H, Han Z, Hallahan DE. Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res 2010; 16: 4968-77.
36. Passarella RJ, Spratt DE, van der Ende AE, Phillips JG, Wu H, Sathiyakumar V, et al. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res 2010; 70: 4550-9.
37. Fujita M, Otsuka Y, Yamada S, Iwakawa M, Imai T. X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility. Cancer Sci 2011; 102: 792-8.
38. Lee WH, Warrington JP, Sonntag WE, Lee YW. Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain. Int J Radiat Oncol Biol Phys 2012; 82: 1559-66.
39. Speake WJ, Dean RA, Kumar A, Morris TM, Scholefield JH, Watson SA. Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol 2005; 31: 869-74.
40. Kumar A, Collins HM, Scholefield JH, Watson SA. Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer. Br J Cancer 2000; 82: 960-5.
41. Xu W, Luo T, Li P, Zhou C, Cui D, Pang B, et al. RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating a(v)b3 expression. Int J Nanomedicine 2012; 7: 915-24.
42. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antian-giogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-79.
43. Egami T, Ohuchida K, Yasui T, Mizumoto K, Onimaru M, Toma H, et al. Up-regulation of integrin beta3 in radioresistant pancreatic cancer impairs adenovirus-mediated gene therapy. Cancer Sci 2009; 100: 1902-7.
44. Rieken S, Habermehl D, Mohr A, Wuerth L, Lindel K, Weber K, et al. Targeting anb3 and anb5 inhibits photon-induced hypermigration of malignant glioma cells. Radiat Oncol 2011; 6: 132.
45. Nguyen QT, Tsien RY. Fluorescence-guided surgery with live molecular navigation-a new cutting edge. Nat Rev Cancer 2013; 13: 653-62.
46. Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 1996; 56: 964-68.
47. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, et al. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 2000; 6: 2829-34.
48. Giustini AJ, Petryk AA, Hoopes PJ. Ionizing radiation increases systemic nanoparticle tumor accumulation. Nanomedicine 2012; 8: 818-21.